Niagen IV launches across Medi-Spa clinics on high-end cruise ships, expanding Niagen Plus’ footprint

Niagen Bioscience, Inc., the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced OneSpaWorld  as the newest Niagen Plus^™ provider, engaged to offer pharmaceutical grade Niagen IV at over 80 Medi-Spa clinics onboard high-end cruise ships. Marking Niagen Bioscience’s first cruise ship clinic partnership, this collaboration brings Niagen IV to guests at sea.

Rob Fried, CEO of Niagen Bioscience, commented, “OneSpaWorld opens a new premium channel at sea, strengthens our rapidly expanding Niagen Plus clinic footprint, and supports our strategy to scale Niagen IV and injections outside of the U.S.”

This partnership extends Niagen Bioscience’s fast-growing clinical channel for Niagen Plus, with Niagen IV and injections available at over 1,200 top healthcare, wellness, and longevity clinics across the U.S. Niagen Bioscience continues to scale Niagen IV through premium medical and wellness providers, and OneSpaWorld introduces an entirely new point of access: high-intent, on-vacation consumers seeking elevated wellness experiences while traveling.

Leonard Fluxman, CEO of OneSpaWorld, remarked, “Today’s travelers are increasingly seeking science-backed wellness experiences while at sea. Niagen IV offers a premium NAD-boosting intravenous solution, providing a premium and innovative service enhancement for travelers committed to prioritizing health and longevity.”

Within its Niagen Plus product portfolio, Niagen Bioscience developed a next-generation intravenous formulation of pharmaceutical-grade Niagen^® (patented nicotinamide riboside) designed to support cellular vitality and healthy aging. Compared to traditional NAD+ IV, the aqueous-based Niagen IV formulation offers a better patient experience, enables 75% shorter infusion times, and delivers a higher, faster rise in NAD+ blood levels—without the severe side effects commonly associated with NAD+ IV (Reyna et al., 2026; Hawkins et al., 2024). The Company recently announced the broadening of its NAD+ precursor intellectual property (IP), with a newly granted patent covering the methods of use of Niagen (patented NR) and derivatives in IV and injectable formulations.

OneSpaWorld provides health, wellness, aesthetics, fitness, and Medi-Spa services across a broad portfolio of cruise ships and itineraries. Niagen IV (500 mg) is now available through Wells Pharma of Houston, a U.S. FDA-registered outsourcing facility, as a premium onboard OneSpaWorld service, with deployment aligned to ship-specific Medi-Spa operations and applicable regulatory requirements. The Niagen IV rollout is expected to meaningfully expand across OneSpaWorld’s fleet footprint, providing a scalable pathway for Niagen Plus to reach new consumers and drive additional demand.

Kris Fishman, CEO, Wells Pharmacy Network, stated, “Wells Pharmacy is proud to compound and distribute pharmaceutical-grade Niagen to qualified clinics, supporting this first-of-its-kind rollout at sea with our rigorous compounding and safety standards.”

Source: BUSINESS WIRE